Ambu stock trades at DKK 69.60 as annual report nears 2026 target date? No question mark allowed

Published on 10/08/2026 at 10:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ambu stock was trading at DKK 69.60 on October 8, 2026, while the annual report date is set for November 5. Q3 organic growth reached 10.3 percent.

Schwarzweiß-Reportage aus dem Operationssaal mit Endoskopie-Technik — Ambu A/S (DK0060946788) dokumentiert schwarzweiß eine dramatische Operationssaal-Szene mit Endoskopie-Ausrüstung im Krankenhaus, Illustration mit AI erstellt.

Ambu stock (ISIN DK0060946788) was trading at DKK 69.60 on Nasdaq Copenhagen on October 8, 2026, down 0.71 percent from the prior close of DKK 70.10. The next scheduled company checkpoint is the annual report for fiscal 2025/26 on November 5, 2026, according to Ambu.

Growth remains led by endoscopy

Ambu reported 10.3 percent organic growth in the third quarter of fiscal 2025/26, while Endoscopy Solutions grew 16 percent and represented 64 percent of revenue, according to Yahoo Finance on August 26, 2026. The comparison matters because Anesthesia and Patient Monitoring returned to positive growth at 1.6 percent after two quarters of negative growth.

Respiratory was the strongest reported area, with organic growth of 17.1 percent in the quarter. That performance contrasts with the more modest recovery in Anesthesia and Patient Monitoring and leaves the endoscopy portfolio as the clearest operating driver in the latest period.

Margin progress meets execution risk

Reported EBIT margin reached 13.5 percent in the third quarter, an improvement of 2.2 percentage points from the same quarter a year earlier, while adjusted EBIT margin was 12.5 percent, according to Yahoo Finance. The company attributed part of the quarterly margin outcome to tariff refunds, foreign exchange effects and one-time commercial and strategic costs.

Management maintained full-year EBIT margin guidance of 12 percent to 14 percent and continued to target cash conversion above 40 percent. For investors, the key test is whether fourth-quarter operating leverage can improve the adjusted margin after the 12.5 percent level reported for the third quarter.

Analyst target remains above market price

UBS downgraded Ambu to Neutral from Buy on September 15, 2026, and cut its price target to DKK 72 from DKK 96, according to MarketScreener. The same source reports a Hold consensus from eight analysts and an average target of DKK 81.77, which is 17.5 percent above the DKK 69.60 market price.

Ambu stock stays below yearly high

Ambu stock was last at DKK 69.60 on Nasdaq Copenhagen on October 8, 2026, at 10:32 a.m. CEST. The 52-week range is DKK 56.25 to DKK 109, while market capitalization is DKK 18.5 billion and trading volume stood at 49,477 shares.